Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT06248840 Terminated - Clinical trials for Nasopharyngeal Carcinoma

Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received IOE while the control group received NGT for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (QOL) after treatment as well as adverse events are compared.

NCT ID: NCT06189482 Terminated - Clinical trials for Nasopharyngeal Carcinoma

Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma

NPC
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received IOE while the control group received NGT for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (QOL) after treatment as well as adverse events are compared.

NCT ID: NCT05653427 Terminated - Clinical trials for Carcinoma, Hepatocellular

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Start date: December 8, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)

NCT ID: NCT05461794 Terminated - Clinical trials for Esophageal Squamous Cell Carcinoma

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Start date: October 3, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of sitravatinib in combination with tislelizumab for the treatment of participants with esophageal squamous cell carcinoma

NCT ID: NCT05437679 Terminated - Prostate Cancer Clinical Trials

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

CHARTER
Start date: July 5, 2022
Phase:
Study type: Observational

This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with non-metastatic disease experiencing biochemical recurrence and castration-resistance (BCRLPC and NMCRPC groups, respectively) who are about to undergo next generation imaging (NGI, such as Axumin® or PSMA PETCT). The investigators will also evaluate subjects with localized indolent prostate cancer who are on active surveillance (AS) as a control population. The CTC and gene expression results will be evaluated for association with disease state and progression and survival.

NCT ID: NCT05375604 Terminated - Clinical trials for Advanced Hepatocellular Carcinoma (HCC)

A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)

Start date: June 28, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase 1 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of exoASO-STAT6 (CDK-004) in patients with advanced Hepatocellular Carcinoma (HCC) and patients with liver metastases from either primary gastric cancer or colorectal cancer (CRC).

NCT ID: NCT05363605 Terminated - Breast Cancer Clinical Trials

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Start date: April 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This first-in-human study evaluates safety, tolerability and distribution of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.

NCT ID: NCT05249569 Terminated - Clinical trials for Hepatocellular Carcinoma

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

Start date: November 4, 2022
Phase: Phase 2
Study type: Interventional

Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden. Treatment beyond progression should be considered when the patient is stable (or improving) symptomatically and if tumor reassessment can be performed within a short period.

NCT ID: NCT05229900 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of SGN-ALPV in Advanced Solid Tumors

Start date: April 21, 2022
Phase: Phase 1
Study type: Interventional

This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.

NCT ID: NCT05219578 Terminated - Clinical trials for Non Small Cell Lung Cancer

RTX-224 Monotherapy in Patients With Solid Tumors

Start date: January 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.